Ibrutinib for the treatment of Mantle Cell Lymphoma (MCL): evaluating the correlation between patient-reported outcomes and durability of response in a Phase 2 study
Rule, S, Goy, A, Martin, P, Ramchandren, R, Alexeeva, J, Popat, R, Avivi, I, Advani, R, Le Gouill, S, Horowitz, N, Yuan, Z, Kranenburg, B, Zhuang, S.H, Deraedt, W, Rizo, A, Wildgust, M, Wang, M
Published in Value in health (01.05.2015)
Published in Value in health (01.05.2015)
Get full text
Journal Article
PSY52 - Ibrutinib for the treatment of Mantle Cell Lymphoma (MCL): evaluating the correlation between patient-reported outcomes and durability of response in a Phase 2 study
Rule, S., Goy, A., Martin, P., Ramchandren, R., Alexeeva, J., Popat, R., Avivi, I., Advani, R., Le Gouill, S., Horowitz, N., Yuan, Z., Kranenburg, B., Zhuang, S.H., Deraedt, W., Rizo, A., Wildgust, M., Wang, M.
Published in Value in health (01.05.2015)
Published in Value in health (01.05.2015)
Get full text
Journal Article
Pegylated Liposomal Doxorubicin (PLD) in Combination with Bortezomib (B) May Provide Therapeutic Advantage for High-Risk Multiple Myeloma Patients Relapsing within 12 Months of Stem Cell Transplant
Kumar, Shaji, Blade, J., Miguel, J. San, Hajek, R., Nagler, A., Sonneveld, P., Spencer, A., Sutherland, H.J., Robak, T., Mundle, S.D., Zhuang, S.H., Harousseau, J.L., Orlowski, R.Z.
Published in Blood (16.11.2007)
Published in Blood (16.11.2007)
Get full text
Journal Article